Hoth Therapeutics And North Carolina State University Initiate Preclinical Gene Therapy Study For The Treatment Of Asthma

NEW YORK, Dec. 9, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, is pleased to announce the initiation of a preclinical study for the treatment of asthma and allergic inflammation in collaboration with North Carolina State University (NC State) beginning on January 1, 2020.

The goal of the study is to determine the best approach for targeting allergic inflammation in the airways with Splice-switching oligonucleotides (SSOs) and establish proof of principle by providing preclinical mouse data to inform consequent toxicology, ADME (absorption, distribution, metabolism and excretion), and Pharmacokinetics (PK) study or how an organism affects the drug.

The initial set of experiments look to establish the delivery of SSOs targeting the gene encoding the FcεRIβ protein in the lungs of mice by using an ultrasonic nebulizer and assessing its distribution and function in mast cells throughout for a period of one year by using RNA (Ribonucleic acid) scope technology. Once effective delivery of SSOs to the lungs has been established and determined that delivery of a target gene SSO reduces allergic airway inflammation in a standard asthma mouse model, HOTH and NC State plan to move on to the second phase of the study.

During the second phase, the aim will be to determine the efficacy of SSO combinations that target FcεRIβ and other genes that function in the IgE receptor pathway, in airway inflammation using humanized mouse models to establish which target gene(s) to move forward with. The study will determine the efficacy, in vivo, by administering SSOs for the target gene(s) and establishing whether targeting FcεRIβ alone or in combination with other genes provides the best therapeutic approach.

Mr. Robb Knie, Chief Executive Officer of Hoth Therapeutics, Inc. commented, "After signing our license agreement with NC State in November 2019, we are pleased to quickly move forward with the design of our preclinical study for asthma. This study will not only allow us to identify and advance drug candidates for asthma and other allergic diseases, but it will also play a key role in reversing the progression of allergic reactions in patients."

About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company's proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visit www.hoththerapeutics.com.

Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

Contacts
Investor Relations Contact:
Phone: (646) 756-2997
Email: [email protected]
www.hoththerapeutics.com

KCSA Strategic Communications
Valter Pinto / Daniela Guerrero
(212) 896-1254 / (212) 682-6300
[email protected]

SOURCE Hoth Therapeutics, Inc.

Related Links

https://hoththerapeutics.com